Navigation Links
Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
Date:9/4/2008

LAIYANG, China, Sept. 4 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the "Company"), a leading pharmaceutical company in the People's Republic of China, today announced that it completed a 40-for-1 reverse stock split of its common stock which will begin trading under the symbol "GNPH."

Upon today's market open, Genesis' common stock will no longer trade under the symbol "GTEC" and will begin trading on a split-adjusted basis under the trading symbol "GNPH."

Following this reverse stock split, the Company has approximately 10,325,000 shares of common stock outstanding.

"We are pleased to complete this reverse stock split of our common stock as part of our efforts to position the company to move to a senior U.S. stock market and improve the marketability and value of our shares," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises. "We expect this adjustment to our capital structure to bring the Company to the attention of new investors and make our shares more attractive to them."

Stockholders who hold their shares in brokerage accounts or "street name" will not be required to take any action to exchange their shares. Stockholders of record who hold share certificates will receive a letter of transmittal requesting that they surrender their old stock certificates for new stock certificates reflecting the adjusted number of shares as a result of the reverse stock split. The Transfer Agent and Registrar for shares of GTEC's common stock is Computershare Trust Company, 350 Indiana St., #800, Golden, Colorado 80401, (303) 262-0600. They will act as the exchange agent for purposes of implementing the exchange of stock certificates.

About Genesis Pharmaceuticals Enterprises, Inc.

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical
'/>"/>

SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th
5. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
6. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
7. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
8. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
9. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
10. Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers
11. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...RY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Bio...the "Company") today announced updated results fro...atients with sarcomas metastatic to the lung in a ...Tissue Oncology Society Meeting held in Miami Beac...resentation, entitled "A Phase II Study of Intrave...
(Date:11/5/2009)...ERSBURG, Md., Nov. 5 Gen...ancial results for the third quarter ended Septemb...llion ($0.04 per share) for the three months ended... million ($0.08 per share) in the comparable quart..., 2009, GenVec,s net loss was $14.1 million ($0.15...
(Date:11/5/2009)...O CORDOVA, Calif., Nov. 5 /PRNewswire-FirstCall/ -...supplier of innovative products for processing and...for the first quarter of fiscal 2010. ,, For th...ported revenues of $5.2 million, a 15 percent incr...arter a year ago. The Company said the key contrib...
(Date:11/5/2009)...VALE, Calif., Nov. 5 Cep...cutives will be speaking at the following investor... via webcast. , , Credit Suisse He...Thursday, 12 November, 2009 at 10 a.m. Mountain Ti...ram, London, England, Tuesday, 1 D...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8Cepheid to Webcast Upcoming Financial Presentations 2
...EAST NORRITON, Pa., Feb. 27 Tengion Inc., a clini... the development of,neo-organs and neo-vessels, an...o its Board of Directors. Mr. Randall brings more ...ive, CFO and CEO at public and private,companies t...device,manufacturing and electronics industries., ...
...SOUTH SAN FRANCISCO, Calif., Feb. 27 Anesiva,Inc....aughlin, the company,s,chief executive officer, wi...ificant Investment Options in Healthcare Conferenc...., To access the live webcast or the subsequent a...om, go to the Investors page, and click on Events...
...RIO DE JANEIRO, Brazil, Feb. 26 One of,Brazil,s l...ofarma,Distribuidora de Produtos Farmaceuticos S.A...as just announced its results for the fourth quart...S FOR THE PERIOD, -- Profarma,s market share brea...ntage points above the share reached in the 3Q07 a...
Other Biology Technology:Tengion Appoints Jeff Randall to Board of Directors 2
(Date:11/4/2009)...,, CARLSBAD, Calif., Oct. 23 Ge...ure biosample management for genomic discovery, me...vid Wellis, Ph.D., GenVault,s President and CEO, w...e taking place on October 26th and 27th in La Joll...ill provide an overview of the company together wi...
(Date:11/4/2009)...,, NEW YORK, Oct. 27 Global Rai...mpany and advanced R&D laboratory, today annou...e and is prepared to actively commercialize its su...dge biometric security offerings. ,, During the...llions of dollars to develop and deploy a series o...
(Date:11/4/2009)...,, CARLSBAD, Calif., Nov. 4 Gen...hat William Brody, M.D., Ph.D., has joined its Boa...idential Chair of the Salk Institute, is an acclai...ior to joining the Salk Institute, Dr. Brody serve...e is a member of the National Academy of Engineeri...
Breaking Biology News(10 mins):GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Brain Fitness Makes Boomers Age Younger 4605 1Brain Fitness Makes Boomers Age Younger 4605 2BioArts International Clones 9 11 Hero Dog Owner to Receive Five Cloned Puppies June 17 in Los Angeles 49158 1BioArts International Clones 9 11 Hero Dog Owner to Receive Five Cloned Puppies June 17 in Los Angeles 49158 2BioArts International Clones 9 11 Hero Dog Owner to Receive Five Cloned Puppies June 17 in Los Angeles 49158 3European Airports Actively Engaging on Reducing CO2 Despite the Crisis 12664 1European Airports Actively Engaging on Reducing CO2 Despite the Crisis 12664 2European Airports Actively Engaging on Reducing CO2 Despite the Crisis 12664 3
...n damage DNA, reducing its ability to replicate an...he development of skin cancers. However, not much ...s altered upon exposure to UV light. Now a group o...method to measure changes in the mechanical proper...r Marszalek and his colleagues have conducted sing...
...MS) tends to go into remission while women are pre...ing neurodegenerative disease, according to Univer...pregnancy-related hormone is responsible for rebui... In a paper to be published in the February 21 iss...rchers from the U of C,s Faculty of Medicine repor...
...ther, more widely used subjects of scientific stud... or mouse. But University of Illinois cell and dev...s it should be. As it turns out, the tiny, seeming... study of germ cells, precursors of eggs and sperm...arian Newmark studies, Schmidtea mediterranea, is ...
Other Biology News:Stretching DNA to the limit 2Pregnancy hormone key to repairing nerve cell damage 2Pregnancy hormone key to repairing nerve cell damage 3Study of planarians offers insight into germ cell development 2
Mycoplasma Testing from AbD Serotec
...Exonuclease-free Klenow Fragment is a genetically ...xonuclease activity has been removed, leaving only...f exonuclease activity makes Exo- Klenow Fragment ...ng of DNA probes by the random primed method, and ...
T4 RNA Ligase from Roche Applied Science
T7 RNA Polymerase from Roche Applied Science
Biology Products: